This is what analysts have to say about China Cord Blood Corp (NYSE:CO) after last week.

July 26, 2017 - By Nellie Frank

 This is what analysts have to say about China Cord Blood Corp (NYSE:CO) after last week.
Investors sentiment decreased to 0.69 in 2016 Q4. Its down 0.08, from 0.77 in 2016Q3. It is negative, as 5 investors sold China Cord Blood Corp shares while 8 reduced holdings. 4 funds opened positions while 5 raised stakes. 6.47 million shares or 1.88% more from 6.35 million shares in 2016Q3 were reported.
Commercial Bank Of America De has invested 0% in China Cord Blood Corp (NYSE:CO). Pnc Service Gru invested in 0% or 10,000 shares. Ontario – Canada-based Bank & Trust Of Montreal Can has invested 0% in China Cord Blood Corp (NYSE:CO). State Street has invested 0% in China Cord Blood Corp (NYSE:CO). Creative Planning stated it has 0% in China Cord Blood Corp (NYSE:CO). Glg Prns Lp stated it has 1.61 million shares or 0.39% of all its holdings. Parametric Port Assoc Limited Liability stated it has 0% in China Cord Blood Corp (NYSE:CO). Morgan Stanley has invested 0% of its portfolio in China Cord Blood Corp (NYSE:CO). Citigroup invested in 0% or 695,471 shares. Renaissance Technology Lc reported 0.01% of its portfolio in China Cord Blood Corp (NYSE:CO). Financial Counselors reported 0.03% of its portfolio in China Cord Blood Corp (NYSE:CO). Wells Fargo And Communications Mn has invested 0% of its portfolio in China Cord Blood Corp (NYSE:CO). Acadian Asset Management Ltd Liability Corporation holds 0.02% of its portfolio in China Cord Blood Corp (NYSE:CO) for 571,602 shares. Credit Suisse Ag, Switzerland-based fund reported 1.16M shares. Gsa Ptnrs Ltd Liability Partnership accumulated 0.01% or 20,400 shares.

China Cord Blood Corp (NYSE:CO) Ratings Coverage

Among 2 analysts covering China Cord Blood (NYSE:CO), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. China Cord Blood had 4 analyst reports since August 21, 2015 according to SRatingsIntel. The rating was maintained by Roth Capital with “Hold” on Friday, August 28. The rating was maintained by TH Capital on Friday, August 21 with “Neutral”. The company was downgraded on Friday, February 5 by Howard Weil. Below is a list of China Cord Blood Corp (NYSE:CO) latest ratings and price target changes.

The stock increased 1.13% or $0.12 during the last trading session, reaching $10.78. About shares traded. China Cord Blood Corp (NYSE:CO) has risen 28.22% since July 26, 2016 and is uptrending. It has outperformed by 11.52% the S&P500.

China Cord Blood Corporation is a provider of cord blood banking services in China. The company has market cap of $1.35 billion. The Firm and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It has a 42.09 P/E ratio. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.

More notable recent China Cord Blood Corp (NYSE:CO) news were published by: Prnewswire.com which released: “China Cord Blood Corporation Announces Termination of Evaluation and …” on April 13, 2017, also Prnewswire.com with their article: “China Cord Blood Corporation Receives Notice of Entry Into Conditional Sale …” published on January 04, 2017, Prnewswire.com published: “China Cord Blood Corporation Receives Notification of Exercise of 7% Senior …” on April 06, 2017. More interesting news about China Cord Blood Corp (NYSE:CO) were released by: Seekingalpha.com and their article: “China Cord Blood (CO) Q3 2017 Results – Earnings Call Transcript” published on February 27, 2017 as well as Prnewswire.com‘s news article titled: “China Cord Blood Corporation to Report Fourth Quarter and Full Year of Fiscal …” with publication date: June 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.